Longeveron (NASDAQ:LGVN) Upgraded to Hold at Wall Street Zen

Longeveron (NASDAQ:LGVN) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings downgraded shares of Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $80.00.

Longeveron Stock Down 4.6%

Shares of NASDAQ LGVN opened at $1.67 on Friday. Longeveron has a 52 week low of $1.31 and a 52 week high of $12.30. The company has a market cap of $5.33 million, a P/E ratio of -0.17 and a beta of -0.19. The business has a 50-day simple moving average of $3.90 and a two-hundred day simple moving average of $6.61.

Longeveron (NASDAQ:LGVN) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($1.75) by $1.56. Longeveron had a negative net margin of 1,977.59% and a negative return on equity of 223.19%. The firm had revenue of $0.29 million during the quarter, compared to analyst estimates of $0.33 million. Equities research analysts anticipate that Longeveron will post -7.20 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Longeveron stock. ADAR1 Capital Management LLC purchased a new position in Longeveron Inc. (NASDAQ:LGVN) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned approximately 0.86% of Longeveron at the end of the most recent reporting period. 10.01% of the stock is owned by institutional investors.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on developing regenerative medicines for serious and life-threatening conditions. The company’s research centers on cell-based therapies intended to support tissue repair, reduce harmful inflammation and promote the body’s natural healing processes.

Longeveron’s lead investigational product is Lomecel-B, an allogeneic cell therapy derived from bone marrow obtained from healthy adult donors. The company has evaluated Lomecel-B in clinical programs addressing hypoplastic left heart syndrome, a rare congenital heart defect in infants, as well as Alzheimer’s disease and aging-related frailty.